On December 12th we hosted our latest 'Facebook Live: Ask the Stem Cell Team' event. This time around we really did mean team. We had a host of our Science Officers answering questions from friends and supporters of CIRM. We got a lot of questions and didn't have enough time to address them all. So … Continue reading Facebook Live: Ask the Stem Cell Team
Retinitis pigmentosa
Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness
The governing Board of the California Institute for Regenerative Medicine (CIRM) yesterday invested $32.92 million to fund the Stem Cell Agency’s first clinical trial in Parkinson’s disease (PD), and to support three clinical trials targeting different forms of vision loss. This brings the total number of clinical trials funded by CIRM to 60. The PD … Continue reading Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness
Breaking bad news to stem cell researchers
It’s never easy to tell someone that they are too late, that they missed the deadline. It’s particularly hard when you know that the person you are telling that to has spent years working on a project and now needs money to take it to the next level. But in science, as in life, it’s … Continue reading Breaking bad news to stem cell researchers
Stem Cell Agency’s Diane Winokur hailed as Visionary
Generally speaking, I am not a huge fan of gala dinners. It’s not that I don’t like seeing people who do remarkable things getting a well-deserved honor. It’s just that the dinners often go on too long and the food is usually not very good (hey, this is San Francisco, those things matter). But last … Continue reading Stem Cell Agency’s Diane Winokur hailed as Visionary
jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa
Stepping out of the darkness into light. That’s how patients are describing their experience after participating in a CIRM-funded clinical trial targeting a rare form of vision loss called retinitis pigmentosa (RP). jCyte, the company conducting the trial, announced 12 month results for its candidate stem cell-based treatment for RP. RP is a genetic disorder … Continue reading jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa
A Patient Advocate’s Personal Manifesto
Janni Lehrer-Stein was just 26 when she was diagnosed with a degenerative eye disease and told she was going to be blind within six months. The doctor who gave her the news told her “But don’t worry, people like you are usually hit and killed by a bus long before they go completely blind.” At … Continue reading A Patient Advocate’s Personal Manifesto
CIRM-Funded Clinical Trials Targeting Brain and Eye Disorders
This blog is part of our Month of CIRM series, which features our Agency’s progress towards achieving our mission to accelerate stem cell treatments to patients with unmet medical needs. This week, we’re highlighting CIRM-funded clinical trials to address the growing interest in our rapidly expanding clinical portfolio. Our Agency has funded a total of … Continue reading CIRM-Funded Clinical Trials Targeting Brain and Eye Disorders
Throwback Thursday: Progress to a Cure for Diseases of Blindness
Welcome back to our “Throwback Thursday” series on the Stem Cellar. Over the years, we’ve accumulated an arsenal of exciting stem cell stories about advances towards stem cell-based cures for serious diseases. This month we’re featuring stories about CIRM-funded clinical trials for blindness. 2017 has been an exciting year for two CIRM-funded clinical trials that … Continue reading Throwback Thursday: Progress to a Cure for Diseases of Blindness
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
jCyte starts second phase of stem cell clinical trial targeting vision loss
Studies show that Americans fear losing their vision more than any other sense, such as hearing or speech, and almost as much as they fear cancer, Alzheimer’s and HIV/AIDS. That’s not too surprising. Our eyes are our connection to the world around us. Sever that connection, and the world is a very different place. For … Continue reading jCyte starts second phase of stem cell clinical trial targeting vision loss